首页> 外文期刊>Fundamental & clinical pharmacology. >The mechanisms of antihyperalgesic effect of topiramate in a rat model of inflammatory hyperalgesia
【24h】

The mechanisms of antihyperalgesic effect of topiramate in a rat model of inflammatory hyperalgesia

机译:托吡酯在炎性痛觉过敏大鼠模型中的抗痛觉过敏作用机制

获取原文
获取原文并翻译 | 示例
           

摘要

Recent studies have shown that topiramate, a structurally novel anticonvulsant, exerts antinociceptive activity in animal models of neuropathic, acute somatic, and visceral pain. This study was aimed to examine: (i) the effects of systemically and locally peripherally administered topiramate in the rat inflammatory pain model and (ii) the potential role and site(s) of gamma-aminobutyric acid (GABA), opioid, and adrenergic receptors in topiramate's antihyperalgesia. Rats received intraplantar (i.pl.) injections of the pro-inflammatory compound carrageenan. A paw pressure test was used to determine: (i) the effect of systemic and local peripheral topiramate on carrageenan-induced hyperalgesia and (ii) the effects of systemic and local peripheral bicuculline (selective GABAA receptor antagonist), naloxone (nonselective opioid receptor antagonist), and yohimbine (selective α2-adrenergic receptor antagonist) on topiramate-induced antihyperalgesia. Systemic topiramate (40-160mg/kg; p.o.) produced a significant dose-dependent reduction in the paw inflammatory hyperalgesia induced by carrageenan. The antihyperalgesic effect of systemic topiramate was significantly decreased by systemic bicuculline (0.5-1mg/kg; i.p.), naloxone (2-5mg/kg; i.p.), and yohimbine (1-3mg/kg; i.p.). Local peripheral topiramate (0.03-0.34mg/paw; i.pl.) also produced significant dose-dependent antihyperalgesia, which was significantly depressed by local peripheral yohimbine (0.05-0.2mg/paw; i.pl.) but not by local peripheral bicuculline (0.15mg/paw; i.pl.) or naloxone (0.1mg/paw; i.pl.). The results suggest that topiramate produces systemic and local peripheral antihyperalgesia in an inflammatory pain model, which is, at least partially, mediated by central GABAA and opioid receptors and by peripheral and most probably central α2-adrenergic receptors. These findings contribute to better understanding of topiramate's action in pain states involving inflammation.
机译:最近的研究表明,托吡酯是一种结构新颖的抗惊厥药,在神经性,急性躯体和内脏痛的动物模型中发挥抗伤害感受的作用。这项研究旨在检查:(i)全身和局部外周给予托吡酯在大鼠炎性疼痛模型中的作用,以及(ii)γ-氨基丁酸(GABA),阿片类药物和肾上腺素的潜在作用和部位托吡酯抗痛觉过敏的受体。大鼠接受足底内(i.pl.)注射促炎化合物角叉菜胶。爪压测试用于确定:(i)全身性和局部性外周托吡酯对角叉菜胶诱发的痛觉过敏的作用,以及(ii)全身性和局部性外周小药(选择性GABAA受体拮抗剂),纳洛酮(非选择性阿片受体拮抗剂)的作用)和育亨宾(选择性α2-肾上腺素能受体拮抗剂)对托吡酯引起的抗痛觉过敏。全身性托吡酯(40-160mg / kg; p.o.)使角叉菜胶引起的爪炎性痛觉过敏显着剂量依赖性降低。全身性比库林(0.5-1mg / kg;腹膜内),纳洛酮(2-5mg / kg;腹腔内)和育亨宾(1-3mg / kg;腹腔内)显着降低了全身性托吡酯的抗镇痛作用。局部外周托吡酯(0.03-0.34mg / paw; i.pl.)也产生明显的剂量依赖性抗痛觉过敏,局部外周育亨宾(0.05-0.2mg / paw; i.pl.)显着抑制了镇痛作用双瓜氨酸(0.15mg / paw; i.pl.)或纳洛酮(0.1mg / paw; i.pl.)。结果表明托吡酯在炎性疼痛模型中产生全身性和局部性外周痛觉过敏,这至少部分地由中枢GABAA和阿片样物质受体以及外周和最可能的中枢α2-肾上腺素受体介导。这些发现有助于更好地了解托吡酯在涉及炎症的疼痛状态下的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号